Patients with acute myeloid leukemia (AML) who relapse after first-line treatment face a substantial health care resource utilization (HCRU) and cost burden, according to a poster presented at Virtual ISPOR 2021.
The majority of patients with acute myeloid leukemia (AML) relapse after first-line treatment, which is associated with substantial health care resource utilization (HCRU) and cost burden. These patients also have a poor prognosis: the median survival after relapse is 4 to 11 months.
A retrospective analysis presented at the Virtual ISPOR 2021 meeting highlighted the substantial HCRU burden and costs in the United States and found that 82% of the costs in the first 12 months after relapse comprise inpatient resource utilization.
“Characterizing hospitalization patterns and associated costs of relapsed AML is important for understanding the burden of relapsed AML and the potential clinical and economic benefits of therapies for AML,” the authors wrote.
The researchers used data from the Premier Healthcare Database to examine annual HCRU and associated costs for patients with diagnosed relapsed AML. The database is a large, geographically diverse, hospital-based, all-payer database containing the administrative, health care utilization, and cost data from more than 1 billion patient encounters from more than 1041 hospitals.
The study included 2290 patients with relapsed AML. To be included, patients needed to be ≥ 18 years; have a relapsed AML diagnosis between January 1, 2016, and March 31, 2019; have a prior visit to the same hospital within 2 years; have no relapsed AML diagnosis in the 2 years before the index period (the relapse date); have no stem cell transplantation in the 2 years before the index period; and have no missing billing records.
The mean (SD) age of the patients included was 61.2 (15.7) years, and approximately half (50.2%) were ≥ 65 years. The majority were male (53.1%), White (77.8%), and on Medicare (51.2%). The mean Charlson Comorbidity Index score was 4.02 (2.66) and the most common condition was diabetes (31.0%), followed by congestive heart failure (19.5%) and chronic obstructive pulmonary disease (19.0%).
In the first 12 months after relapse, patients incurred 1798 inpatient hospitalizations:
The mean (SD) cost per visit was $34,209 ($33,838) for inpatient admissions, $19,050 ($19,019) for ICU admissions, and $1793 ($1964) for outpatient visits. In addition, the total cost for patients with AML relapse was $169,643,544.
Slightly less than half (48.4%) had an elective admission, which meant their “condition permitted adequate time to schedule the availability of a suitable accommodation,” while 29.9% were considered emergency, 17.6% urgent, and 4.1% other.
Most (69.4%) patients were discharged home after the visit; however, 6.4% died in the hospital. In addition, 6.4% were discharged to hospice care and 6.3% were transferred to another facility. For 11.2% of the patients, the discharge was other or unknown. The mean length of follow-up was 187 days for patients.
“This study demonstrates significant disease burden, which suggests the need for therapies that would delay relapse and improve survival in patients with AML,” the researchers concluded.
Reference
Huggar D, Knoth R, Cao Z, Lipkin C, Copher R, LeBlanc TW. Annual healthcare resource utilization and costs in US patients diagnosed with relapsed acute myeloid leukemia. Presented at: Virtual ISPOR 2021; May 17-20. Poster PCN51.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Emergency Department Risk Model: Timely Identification of Patients for Outpatient Care Coordination
May 14th 2024The authors created a machine learning–based model to identify patients with major depressive disorder in the primary care setting at high risk of frequent emergency department visits, enabling prioritization for a care coordination program.
Read More